quisinostat and romidepsin share 12 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.800 means 80% of the combined target set is bound by both compounds. The IDF-weighted score of 0.792 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do quisinostat and romidepsin have in common?
quisinostat and romidepsin share 12 molecular targets with a Jaccard similarity of 80%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can quisinostat and romidepsin be combined?
quisinostat and romidepsin share 12 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: quisinostat or romidepsin?
In the BiohacksAI corpus: quisinostat has 0 PubMed-indexed studies, romidepsin has 0 studies.